CAJ | 학술논문

目的：观察紫杉醇联合卡铂治疗晚期非小细胞肺癌的疗效及不良反应。方法32例晚期非小细胞肺癌均接受化疗。具体方案：紫杉醇175mg/㎡（3h 静脉滴注），d1；卡铂80mg/㎡ d2，21天为1周期,2个周期后评价疗效和毒副反应。结果全组32例中，CR 1例，PR16例，SD 8例 PD 7例，总有效率为53.1%，疾病控制率为78.1%，中位生存期11.5个月。主要毒副反应为骨髓抑制、胃肠道反应、周围神经毒性、肌肉关节疼痛、肾功能损害。结论紫杉醇联合卡铂方案治疗晚期非小细胞肺癌疗效好，毒副反应可耐受。
목적：관찰자삼순연합잡박치료만기비소세포폐암적료효급불량반응。방법32례만기비소세포폐암균접수화료。구체방안：자삼순175mg/㎡（3h 정맥적주），d1；잡박80mg/㎡ d2，21천위1주기,2개주기후평개료효화독부반응。결과전조32례중，CR 1례，PR16례，SD 8례 PD 7례，총유효솔위53.1%，질병공제솔위78.1%，중위생존기11.5개월。주요독부반응위골수억제、위장도반응、주위신경독성、기육관절동통、신공능손해。결론자삼순연합잡박방안치료만기비소세포폐암료효호，독부반응가내수。
Objective To evaluate the efficacy and toxicities of Paclitaxel combined with Carboplatin in the treatment of the patients with advanced non-small cell lung cancer. Methods All the 32 patients with advanced non-small cell lung cancer were treated with chemotherapy.The regimen: Paclitaxel 175mg/ ㎡ in day 1 and carboplatin 80mg/ ㎡ in day 2 .The chemotherapy was repeated every 21 days.The efficacy and toxicities were evaluated after 2 cycles of chemotherapy.Results Of the 32 patients,CR were observed in 1 patient,PR in 16 patients,SD in8 patients,and PD in 7 patients.The total response rate was53.1%,The disease control rate was 78.1%,The median survival time was 11.5 months.The major toxicities included my closuppression,gastrointestinal reaction,peripheral nerve toxicity ,pain of muscle and joint,renal function lesion. Conclusion Paclitaxel combined with is carboplatin effective in the treatment of patients with advanced non-small cell lung cancer . Its toxicities can be tolerated.